Published in Pharmacol Biochem Behav on November 01, 1992
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci (2011) 1.83
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) (2005) 1.35
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration. Pharmacol Biochem Behav (2007) 1.25
Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats. Addict Biol (2011) 1.21
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev (2010) 1.15
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacology (Berl) (2003) 1.11
Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11
Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) (2005) 1.09
Nicotine and hippocampus-dependent learning: implications for addiction. Mol Neurobiol (2006) 1.09
Tobacco addiction and the dysregulation of brain stress systems. Neurosci Biobehav Rev (2012) 1.09
Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl) (2004) 1.08
Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology (2009) 1.08
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci (2008) 1.07
Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology (Berl) (2008) 1.07
Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology (Berl) (2004) 1.04
Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology (2009) 1.03
Withdrawal from chronic nicotine in adolescent and adult rats. Pharmacol Biochem Behav (2006) 1.03
Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet (2011) 1.03
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol Biochem Behav (2010) 1.00
Mechanistic insights into nicotine withdrawal. Biochem Pharmacol (2011) 0.98
Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol Biochem Behav (2009) 0.97
Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence. Neuropsychopharmacology (2012) 0.95
Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl) (2008) 0.91
Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci (2013) 0.91
Historical and current perspective on tobacco use and nicotine addiction. Trends Neurosci (2011) 0.91
Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS One (2011) 0.90
Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology (Berl) (2008) 0.90
Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides (2008) 0.90
Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. Addict Biol (2013) 0.89
Exposure to chronic intermittent nicotine vapor induces nicotine dependence. Pharmacol Biochem Behav (2010) 0.89
Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. Front Psychiatry (2013) 0.87
Potentiated startle as a measure of the negative affective consequences of repeated exposure to nicotine in rats. Psychopharmacology (Berl) (2009) 0.87
The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur Neuropsychopharmacol (2010) 0.86
Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology (Berl) (2010) 0.86
Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. Pharmacol Biochem Behav (2010) 0.85
The endocannabinoid system: a new molecular target for the treatment of tobacco addiction. CNS Neurol Disord Drug Targets (2008) 0.85
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl) (2007) 0.84
Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats. Psychopharmacology (Berl) (2005) 0.84
Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc Natl Acad Sci U S A (1996) 0.84
Nicotine vapor inhalation escalates nicotine self-administration. Addict Biol (2012) 0.83
Desensitization of δ-opioid receptors in nucleus accumbens during nicotine withdrawal. Psychopharmacology (Berl) (2010) 0.83
Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Influence of environmental enrichment on hypothalamic-pituitary-adrenal (HPA) responses to single-dose nicotine, continuous nicotine by osmotic mini-pumps, and nicotine withdrawal by mecamylamine in male and female rats. Behav Brain Res (2012) 0.82
Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine. Psychopharmacology (Berl) (2012) 0.82
Decreases in brain reward function reflect nicotine- and methamphetamine-withdrawal aversion in rats. Curr Neuropharmacol (2011) 0.81
Sexually diergic hypothalamic-pituitary-adrenal (HPA) responses to single-dose nicotine, continuous nicotine infusion, and nicotine withdrawal by mecamylamine in rats. Brain Res Bull (2011) 0.81
Neonatal ethanol exposure produces a hyperalgesia that extends into adolescence, and is associated with increased analgesic and rewarding properties of nicotine in rats. Psychopharmacology (Berl) (2003) 0.81
Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology (2013) 0.80
Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats. Psychopharmacology (Berl) (2003) 0.80
Increased pain in response to mechanical or thermal stimulation in a rat model of incision-induced pain with nicotine dependence and withdrawal. Exp Ther Med (2013) 0.80
A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. Sci Rep (2016) 0.79
The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology (Berl) (2008) 0.79
The role of NMDA receptor antagonists in nicotine tolerance, sensitization, and physical dependence: a preclinical review. Yonsei Med J (2008) 0.79
Nicotine withdrawal and kappa-opioid receptors. Psychopharmacology (Berl) (2009) 0.79
Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure. Proc Natl Acad Sci U S A (2016) 0.78
Effects of chronic nicotine, nicotine withdrawal and subsequent nicotine challenges on behavioural inhibition in rats. Psychopharmacology (Berl) (2011) 0.78
Trait differences in response to chronic nicotine and nicotine withdrawal in rats. Psychopharmacology (Berl) (2013) 0.78
New mechanisms and perspectives in nicotine withdrawal. Neuropharmacology (2014) 0.77
A neurobiological basis for nicotine withdrawal. Proc Natl Acad Sci U S A (2007) 0.77
Translational research in nicotine dependence. Cold Spring Harb Perspect Med (2013) 0.77
Substance use modulates stress reactivity: Behavioral and physiological outcomes. Physiol Behav (2016) 0.76
Reinforcer devaluation as a consequence of acute nicotine exposure and withdrawal. Psychopharmacology (Berl) (2014) 0.76
Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats. Eur Neuropsychopharmacol (2016) 0.75
Blockade of cholinergic transmission elicits somatic signs in nicotine-naïve adolescent rats. Front Pharmacol (2015) 0.75
Removal of continuous nicotine infusion produces somatic but not behavioral signs of withdrawal in mice. Pharmacol Biochem Behav (2009) 0.75
Self-Administered Nicotine Suppresses Body Weight Gain Independent of Food Intake in Male Rats. Nicotine Tob Res (2016) 0.75
MEMRI is a biomarker defining nicotine-specific neuronal responses in subregions of the rodent brain. Am J Transl Res (2017) 0.75
Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl) (2016) 0.75
The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. Behav Brain Res (2017) 0.75
Interactions between nicotine and drugs of abuse: a review of preclinical findings. Am J Drug Alcohol Abuse (2016) 0.75
Metabotropic glutamate receptor 5 as a potential target for smoking cessation. Psychopharmacology (Berl) (2016) 0.75
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant (2014) 2.67
Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology (1992) 2.09
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav (2000) 1.93
Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology (1993) 1.92
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol (1995) 1.82
Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology (1995) 1.81
Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med (1992) 1.80
OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant (2015) 1.79
Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant (2006) 1.66
Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med (1991) 1.58
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology (1997) 1.54
Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg (1996) 1.51
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant (2012) 1.50
Differential expression of Ia by murine keratinocytes and gut epithelium in response to recombinant gamma-interferon. J Invest Dermatol (1989) 1.46
The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation (1995) 1.43
Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (1998) 1.41
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
Reversal of chronic rejection after treatment failure with FK506 and RS61443. Transplantation (1993) 1.38
A genetic recombination map of foot-and-mouth disease virus. J Gen Virol (1975) 1.36
Increased waiting time for liver transplantation results in higher mortality. Transplantation (1997) 1.34
An extended genetic recombination map for foot-and-mouth diseases virus. J Gen Virol (1977) 1.27
Liver transplantation for fulminant hepatic failure. Arch Surg (1993) 1.23
Liver transplantation for severe Amanita phalloides mushroom poisoning. Am J Surg (1990) 1.23
Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology (1991) 1.21
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19
Biliary secretion of fluid-phase markers by the isolated perfused rat liver. Role of transcellular vesicular transport. J Clin Invest (1985) 1.18
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology (1996) 1.17
MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol (1991) 1.17
Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology (1994) 1.14
Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation (1998) 1.13
Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation (1996) 1.13
The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) (1994) 1.13
Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg (1998) 1.13
Involvement of prostaglandins in the immune alterations caused by the exposure of mice to ultraviolet radiation. J Immunol (1986) 1.12
Split liver transplantation for two adult recipients: an initial experience. Am J Transplant (2001) 1.07
Expression of Ia antigen on epidermal keratinocytes after the grafting of normal skin to nude mice. J Immunol (1983) 1.07
Characterization of the metabolism inhibition antigen of Mycoplasma arthritidis. Infect Immun (1985) 1.07
Fluid phase endocytosis by cultured rat hepatocytes and perfused rat liver: implications for plasma membrane turnover and vesicular trafficking of fluid phase markers. Proc Natl Acad Sci U S A (1986) 1.06
Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology (1998) 1.05
Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation (1998) 1.04
Prevalence of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) on retail meat in Iowa. J Infect Public Health (2011) 1.03
Gastric angiodysplasia. Radiology (1981) 1.03
Changes in quality of life after liver transplantation among adults. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). Liver Transpl Surg (1997) 1.01
Rat hepatocytes exhibit basolateral Na+/HCO3- cotransport. J Clin Invest (1989) 1.01
The use of the T tube after orthotopic liver transplantation. Transplantation (1996) 1.01
Liver and intestine transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.00
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation (1998) 1.00
Deletions of the terminal sequences in the genomes of the white pock (u) and host-restricted (p) mutants of rabbitpox virus. J Gen Virol (1980) 1.00
Percutaneous transhepatic portal vein angioplasty and stent placement after liver transplantation: early experience. J Vasc Interv Radiol (1990) 0.99
Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes. Liver Transpl Surg (1997) 0.98
Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology (1994) 0.98
Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology (1999) 0.98
Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology (1996) 0.97
Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology (1995) 0.97
Fulminant hepatic failure. Med Clin North Am (1993) 0.96
Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology (1996) 0.96
Chinese herbal medicine, fulminant hepatitis, and liver transplantation. Am J Gastroenterol (1996) 0.95
Bronchobiliary fistula: management with percutaneous catheter drainage of a subphrenic abscess. J Trauma (1982) 0.95
Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) (1993) 0.94
Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium. Pharmacol Biochem Behav (1997) 0.93
The role of p53 in regulating antiviral T cell responses. J Immunol (2001) 0.93
Modification of the immunogenic properties of chemically induced tumors arising in hosts treated concomitantly with ultraviolet light. J Immunol (1980) 0.92
Acidic vesicles in cultured rat hepatocytes. Identification and characterization of their relationship to lysosomes and other storage vesicles. Gastroenterology (1987) 0.92
Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav (2001) 0.92
Transjugular intrahepatic portosystemic shunt as a form of treatment for portal hypertension: indications and contraindications. Adv Intern Med (1997) 0.92
Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg (1996) 0.91
Phenotypic and physical characteristics of the lymphoid cells involved in the immunity to syngeneic UV-induced tumors. J Immunol (1979) 0.91
Transjugular intrahepatic portosystemic shunts: preliminary results in 25 patients. J Vasc Surg (1992) 0.90
Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer (1996) 0.90
Forward and inverse potential field solutions for cardiac strands of cylindrical geometry. IEEE Trans Biomed Eng (1985) 0.90
Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant (2006) 0.90
Biogenesis of vaccinia: complementation and recombination analysis of one group of conditional-lethal mutants defective in envelope self-assembly. Virology (1979) 0.89
Amiloride and amiloride analogs inhibit Na+/K+-transporting ATPase and Na+-coupled alanine transport in rat hepatocytes. Biochim Biophys Acta (1988) 0.89
Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg (1995) 0.88
Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation. Hepatology (1996) 0.88
Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation (1997) 0.88
The impact of surgical complications after liver transplantation on resource utilization. Arch Surg (1997) 0.88
Synthesis of virus DNA and polypeptides by temperature-sensitive mutants of rabbitpox virus. J Gen Virol (1980) 0.88
Methods to estimate and analyze medical care resource use. An example from liver transplantation. Int J Technol Assess Health Care (1999) 0.87
Na+-H+ exchange activity in rat hepatocytes: role in regulation of intracellular pH. Am J Physiol (1989) 0.87
Nonoperative management of biliary leaks after orthotopic liver transplantation. Transplantation (1993) 0.87
Treatment of hepatic failure--1996: current concepts and progress toward liver dialysis. Am J Kidney Dis (1996) 0.84
Selection of patients for liver transplantation in 1997 and beyond. Clin Liver Dis (1997) 0.84
Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol Biochem Behav (1996) 0.84
Modulation of immunoregulatory responses directed toward various tumor antigens within hosts possessing distinct immunologic potentials. J Immunol (1980) 0.84